Compare TGTX & BC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | BC |
|---|---|---|
| Founded | 1993 | 1845 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.7B |
| IPO Year | 2008 | N/A |
| Metric | TGTX | BC |
|---|---|---|
| Price | $31.76 | $70.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $49.80 | ★ $77.67 |
| AVG Volume (30 Days) | ★ 2.0M | 956.9K |
| Earning Date | 05-04-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.30 | $9.74 |
| Revenue Next Year | $24.55 | $5.15 |
| P/E Ratio | $11.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $41.00 |
| 52 Week High | $46.48 | $90.25 |
| Indicator | TGTX | BC |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 38.34 |
| Support Level | $29.81 | $60.34 |
| Resistance Level | $32.96 | $73.07 |
| Average True Range (ATR) | 1.40 | 2.20 |
| MACD | 0.31 | 0.46 |
| Stochastic Oscillator | 87.22 | 28.49 |
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns 442 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.